Studies related to Homocysteine and Boron

Effects Of Calcium Fructoborate On Levels Of C-Reactive Protein, Total Cholesterol, Low-Density Lipoprotein, Triglycerides, IL-1β, IL-6, And MCP-1: A Double-blind, Placebo-controlled Clinical Study

Effect Decrease
Values Mean and SD. Placebo: before 19.6 ± 12.7, after 19.1 ± 12.6. Low dose: before 16.4 ± 9.9, after 15.0 ± 9.1. High dose: before 16.8 ± 10.4, after 14.4 ± 8.9.
Trial Design Randomized trial
Trial Length 2-4 Weeks
Number of Subjects 90
Sex Both Genders
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 90 healthy participants were allocated to take placebo, 56 mg (1.5 mg of boron) or 112 mg (3 mg of boron) of calcium fructoborate, for 30 days.

Both boron groups saw comparable reductions in total cholesterol, LDL, and triglycerides that were statistically significant compared with placebo. HDL and glucose weren't notably changed. C-reactive protein, IL-1b, IL-6, MCP-1 were reduced more in the boron groups while than placebo, and statistically significant for the high dose group for all but c-reactive protein, and significant for the low dose for group for all but IL-6, and c-reactive protein. Homocysteine was reduced more in the boron groups, though it's unclear if the difference was statistically significant compared with placebo.